SPONSOR
Anna Raciborska
Total Trials
2
Recruiting
2
Phases
Phase 3, Phase 2
Conditions studied: Histiocytosis
Anna Raciborska is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Histiocytosis.
The trial portfolio spans Phase 3, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Anna Raciborska
How many clinical trials has Anna Raciborska sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Anna Raciborska, of which 2 are actively recruiting participants. These trials cover conditions including Histiocytosis. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Anna Raciborska research focus on?
Anna Raciborska clinical trials span Histiocytosis. The research pipeline includes Phase 3, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Anna Raciborska clinical trial?
To participate in a Anna Raciborska trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Anna Raciborska trials with current recruitment status updated daily.
Clinical Trials by Anna Raciborska
NCT04943211 Phase 3
Recruiting
Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging
Histiocytosis
NCT04943198 Phase 2
Recruiting
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Histiocytosis
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology